⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6892587 | 0.87 | — | — | |
| SCHEMBL9517488 | 0.83 | PTPN7 (0.45) | — | |
| SCHEMBL31726039 | 0.78 | HMGCR (0.35) | — | |
| SCHEMBL3104639 | 0.76 | — | — | |
| SCHEMBL10233415 | 0.76 | — | — | |
| SCHEMBL577217 | 0.76 | — | — | |
| SCHEMBL6720344 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL17727572 | 0.74 | — | — | |
| SCHEMBL9007652 | 0.74 | — | — | |
| SCHEMBL30565398 | 0.74 | ALOX15 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20250186627-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-12 | — | — | US | disclosed |
| US-20250161501-A1 | Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-05-22 | — | — | US | disclosed |
| WO-2025054727-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-20 | — | — | WO | disclosed |
| US-12246076-B2 | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-11 | — | — | US | disclosed |
| EP-4499663-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | Provincial Health Services Authority (CA) | 2025-02-05 | — | — | EP | disclosed |
| EP-4486756-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | Provincial Health Services Authority (CA) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20240123099-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-04-18 | — | — | US | disclosed |
| US-11203579-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2021-12-21 | — | — | US | disclosed |
| US-20210171477-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2021-06-10 | — | — | US | disclosed |
| EP-3601228-A1 | MICROBIOCIDAL QUINOLINE (THIO)CARBOXAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172133-A1 | MICROBIOCIDAL QUINOLINE (THIO)CARBOXAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-09-27 | — | — | WO | disclosed |
| EP-1999119-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | Abbott Laboratories (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007095602-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
| EP-1330429-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6521790-B2 | A most preferred compound is (2R)-2-propyl-4-hexynamide, an analog of valproic acid. treating seizures, migraine, psychiatric disorders, neuropathic pain and restlessness syndrome; neuroprotecting a cerebral insult; | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
| US-20020123528-A1 | Alkynyl amides and their therapeutic applications | ABBVIE INC. | 2002-09-05 | — | — | US | disclosed |
| WO-2002036546-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-05-10 | — | — | WO | disclosed |